Table 3.
Patient characteristics overall and by clusters
| Characteristic | Total (n=242) | Cluster 1 (n=51) | Cluster 2 (n=19) | Cluster 3 (n=86) | Cluster 4 (n=22) | Cluster 5 (n=42) | Cluster 6 (n=22) |
|---|---|---|---|---|---|---|---|
| Age, yr | 26.40 (21.43) | 21.73 (16.24) | 32.00 (22.28) | 19.16 (19.57) | 30.41 (27.26) | 36.69 (20.62) | 37.09 (21.26) |
| Pediatric patients | 52% (125) | 53% (27) | 47% (9) | 71% (61) | 50% (11) | 29% (12) | 23% (5) |
| Adult patients | 48% (117) | 47% (24) | 53% (10) | 29% (25) | 50% (11) | 71% (30) | 77% (17) |
| Male | 54% (131) | 61% (31) | 37% (7) | 53% (46) | 41% (9) | 64% (27) | 50% (11) |
| Blacka | 33% (78) | 33% (16) | 11% (2) | 33% (28) | 27% (6) | 45% (19) | 32% (7) |
| Hispanic | 24% (57) | 31% (16) | 32% (6) | 27% (23) | 9% (2) | 17% (7) | 14% (3) |
| Disease cohort | |||||||
| MCD/MCD-like | 49% (119) | 51% (26) | 58% (11) | 66% (57) | 27% (6) | 33% (14) | 23% (5) |
| FSGS | 51% (123) | 49% (25) | 42% (8) | 34% (29) | 73% (16) | 67% (28) | 77% (17) |
| eGFR at biopsyb | 90.39 (44.42) | 93.20 (40.31) | 93.01 (34.91) | 98.35 (38.41) | 90.19 (47.65) | 71.58 (36.63) | 86.57 (77.83) |
| UPCR at biopsya | 5.32 (7.72) | 2.18 (3.01) | 5.73 (5.95) | 7.98 (9.83) | 3.61 (4.62) | 5.29 (8.90) | 3.97 (3.15) |
| On immunosuppressive medications at biopsy | 34% (83) | 25% (13) | 16% (3) | 53% (46) | 27% (6) | 24% (10) | 23% (5) |
| Rate of complete remission during study follow-up (no. of events per 100 person-yr of follow-up)c | 37.57 | 22.08 | 29.49 | 78.32 | 30.50 | 28.80 | 13.75 |
| Rate of ≥40% decline in eGFR with eGFR<60 ml/min per 1.73 m2 or ESKD during study follow-up (no. of events per 100 person-yr of follow-up)d | 3.99 | 5.38 | 7.09 | 0.85 | 2.77 | 6.70 | 9.58 |
Cluster 1: fewer changes, cluster 2: thin GBM, cluster 3: classic MCD, cluster 4: abnormal GBM texture, cluster 5: thick GBM, cluster 6: EC changes.
a
Missing <5%.
b
Missing <10%.
c
n=197 (n=25 had complete remission at biopsy; n=11 missing UPCR at biopsy; n=19 had no follow-up UPCR).
d
n=209 (n=24 missing eGFR at biopsy; n=9 had no follow-up eGFR).